OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE.

J. Sparks, Z. Wallace, A. Seet, M. Gianfrancesco, Z. Izadi, K. Hyrich, A. Strangfeld, L. Gossec, L. Carmona, E. Mateus, S. Lawson-Tovey, L. Trupin, S. Rush, G. Schmajuk, P. Katz, L. Jacobsohn, S. Al Emadi, L. Wise, E. Gilbert, A. Duarte-Garcia, M. Valenzuela-Almada, T. Hsu, K. D'silva, N. Serling-Boyd, P. Dieudé, E. Nikiphorou, V. Kronzer, N. Singh, M.F. Ugarte-Gil, B. Wallace, A. Akpabio, R. Thomas, S. Bhana, W. Costello, R. Grainger, J. Hausmann, J. Liew, E. Sirotich, P. Sufka, P. Robinson, P. Machado, J. Yazdany, on behalf of COVID-19 Global Rheumatology Alliance